

Table S1. Phenotypic characteristics of CR strains included in this study. Reduced susceptibility to antimicrobial antimicrobials is indicated in bold.

| Isolate | MIC (mg/L) ¹ | | | | | | | | | | | | | | | |
|----------------------------------|-------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|-------------------|-------------------|-------------------|-------------------|-------------------|--------------------|-------------------|-------------------|
| | AZT ² | C/T ³ | COL ⁴ | P/T ⁵ | TGC ⁶ | IMI ⁷ | IMR ⁸ | FEP ⁹ | CZA ¹⁰ | AMI ¹¹ | ERV ¹² | CFD ¹³ | FOS ¹⁴ | MERO ¹⁵ | TOB ¹⁶ | MEV ¹⁷ |
| CRE CFD-susceptible | >32 | >8/4 | ≤0.5 | >32/4 | ≤0.5 | >8 | 0.5/4 | >16 | 1/4 | ≤2 | 0.25 | 0.5 | ≤16 | >16 | ≤0.5 | 0.12/8 |
| CRE CFD-resistant | >32 | >8/4 | >16 | >32/4 | 1 | >8 | >8/4 | >16 | >14/4 | 16 | >0.5 | >8 | 32 | >16 | >4 | 16/8 |
| CR-Pa CFD-susceptible | >32 | >8/4 | >16 | 8/4 | >1 | >8 | 8/4 | 16 | 4/4 | 8 | >0.5 | 2 | >64 | >16 | >4 | >16/8 |
| CR-Pa CFD-resistant | 16 | >8/4 | 1 | 16/4 | >1 | >8 | 2/4 | >16 | 16/4 | 32 | 0.5 | 4 | >64 | 4 | >4 | 4/8 |
| CR-Ab CFD-susceptible | 32 | >8/4 | 8 | >32/4 | ≤0.5 | >8 | >8/4 | >16 | >16/4 | >32 | 0.25 | 0.5 | 64 | >16 | >4 | >16/8 |
| CR-Ab CFD-resistant | >32 | >8/4 | ≤0.5 | >32/4 | ≤0.5 | >8 | >8/4 | >16 | >16/4 | >32 | 0.12 | >8 | 32 | >16 | >4 | >16/8 |

¹ Applying EUCAST breakpoint; ² AZT, aztreonam; ³ C/T, ceftolozane/tazobactam (constant 4 mg/L); ⁴ COL, colistin; ⁵ P/T, piperacillin/tazobactam (constant 4 mg/L); ⁶ TGC, tigecycline; ⁷ IMI, imipenem; ⁸ IMR, imipenem/relebactam (constant 4 mg/L); ⁹ FEP, cefepime; ¹⁰ CZA, ceftazidime/avibactam (constant 4 mg/L); ¹¹ AMI, amikacin; ¹² ERV, eravacycline; ¹³ CFD, cefiderocol; ¹⁴ FOS, fosfomycin; ¹⁵ MERO, meropenem; ¹⁶ TOB, tobramycin; ¹⁷ MEV, meropenem/vaborbactam (constant 8 mg/L).